Company profile: Oncocyte
1.1 - Company Overview
Company description
- Provider of blood-based and gene expression tests and biopharma services: DetermaCNI detects cancer progression early via cell-free DNA instability; DetermaIO assesses the tumor immune microenvironment to identify immunotherapy benefit; VitaGraft Kidney/Liver quantify donor-derived cell-free DNA to monitor transplant health and detect rejection; GraftAssure uses droplet digital PCR; and tissue- and blood-based biomarker-driven clinical trial support.
Products and services
- DetermaIO: A gene expression-based test that assesses the tumor immune microenvironment to identify patients likely to benefit from immunotherapy in oncology decision-making
- DetermaCNI: A blood-based test that detects cancer progression early after treatment initiation by measuring cell-free DNA instability for timely therapeutic assessment
- Biopharma Services: Biomarker-driven services leveraging tissue-based and blood-based technologies to support clinical trials and biomarker-driven drug development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oncocyte
Atara Biotherapeutics
HQ: United States
Website
- Description: Provider of off-the-shelf, allogeneic T-cell immunotherapies, conducting clinical studies to evaluate safety and efficacy; offering expanded access to investigational drugs for treatment use; providing educational grants in T-cell immunotherapy; and supplying healthcare providers with information on products and clinical application.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atara Biotherapeutics company profile →
eTheRNA Immunotherapies
HQ: Belgium
Website
- Description: Provider of mRNA and lipid nanoparticle solutions for nucleic acid drug delivery, offering LNP platforms and customized LNP development using proprietary ionizable lipid libraries, plus LNP formulations for systemic cancer vaccines, intra-tumoral immuno-oncology, intramuscular prophylactic vaccines, and autoimmune diseases designed to maximize mRNA expression, efficacy, tolerability, and immune tolerance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTheRNA Immunotherapies company profile →
Medivation
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on rapid development of small‑molecule drugs to treat serious diseases with limited treatment options, including the development of MDV3100 for multiple stages of advanced prostate cancer in collaboration with Astellas Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medivation company profile →
Incyclix Bio
HQ: United States
Website
- Description: Provider of small molecule CDK inhibitors for the treatment of advanced and resistant cancers, including INX-315, a selective CDK2 inhibitor in clinical development that targets abnormal cell proliferation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incyclix Bio company profile →
ALX Oncology
HQ: United States
Website
- Description: Provider of preclinical-stage immuno-oncology therapies for cancer, including Evorpacept (ALX148), a next-generation CD47 blocking therapeutic with high affinity for CD47 and designed to avoid hematologic toxicities, used in combination with anti-cancer agents to enhance immune activation and treat various cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ALX Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oncocyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oncocyte
2.2 - Growth funds investing in similar companies to Oncocyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oncocyte
4.2 - Public trading comparable groups for Oncocyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →